23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Crinetics Pharmaceuticals, Inc. › 2025-2026

Crinetics Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Crinetics Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 290Asset managers, any item
  • 1,887Fund votes
  • June 18, 2026Meeting date

Results at a glance

Meeting of June 18, 2026: 5 items on Crinetics Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026: 2 approved · 3 passed (calculated).

Dissent

Significant dissent: 2 directors (25.5%, 24.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Crinetics Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Crinetics Pharmaceuticals, Inc.

These tallies are Crinetics Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Crinetics Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 18, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Caren Deardorf 73,454,076---- 23,532,3285,044,011 76%Passed (calculated)—
Elect Director: Weston Nichols, Ph.D. 90,208,564---- 6,777,8405,044,011 93%Passed (calculated)—
Elect Director: Stephanie S. Okey, M.S. 72,225,313---- 24,761,0915,044,011 74%Passed (calculated)—
2. Ratification of Selection of Independent Registered Public Accounting Firm 101,675,974341,72712,714 ---- 99.7%Approved—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers 91,657,9922,698,5382,629,874 --5,044,011 97%Approved—

Source: Crinetics Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.

How asset managers voted at the Crinetics Pharmaceuticals, Inc. 2025-2026 meeting

290 asset managers disclosed a vote on at least one Crinetics Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Caren Deardorf

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 73,454,076WITHHELD: 23,532,328
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Caren Deardorf

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Caren Deardorf”): 73,454,076 for, 23,532,328 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 41,526,369 for, 6,242,834 withheld, 54 abstained.

FOR
FOR: 41,526,369ABSTAIN: 54WITHHOLD: 6,242,834
Largest asset managers voting on “To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual mee” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,889,1360 00For
Vanguard13,888,2830 540For
T. Rowe Price3,737,5030 01,242,241Mixed
BlackRock2,339,6200 00For
JANUS INVESTMENT FUND393,8850 0767,773Mixed
Bridge Builder Trust34,9180 0936,672Withhold
JPMorgan847,2770 00For
Charles Schwab836,9540 00For
DRIEHAUS MUTUAL FUNDS00 0759,548Withhold
Columbia Threadneedle741,7140 00For
American Century00 0722,721Withhold
Prudential/PGIM357,5330 098,165Mixed
Hartford367,6230 00For
TIAA356,5950 00For
IMPAX FUNDS SERIES TRUST I350,0000 00For
AMG FUNDS255,8120 00For
Jackson National00 0244,313Withhold
Equitable156,3560 075,390Mixed
Victory Capital7540 0226,114Withhold
Voya00 0201,990Withhold
TRUST FOR PROFESSIONAL MANAGERS00 0170,496Withhold
John Hancock73,5400 055,795Mixed
Dimensional00 0128,939Withhold
AIG/SunAmerica00 0120,117Withhold
Brinker Capital Destinations Trust2,3110 0103,846Withhold

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Elect Director: Stephanie S. Okey, M.S.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 72,225,313WITHHELD: 24,761,091
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Stephanie S. Okey, M.S.

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stephanie S. Okey, M.S.”): 72,225,313 for, 24,761,091 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 41,466,576 for, 6,302,626 withheld, 55 abstained.

FOR
FOR: 41,466,576ABSTAIN: 55WITHHOLD: 6,302,626
Largest asset managers voting on “To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual mee” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,889,1360 00For
Vanguard13,882,6880 555,595For
T. Rowe Price3,737,5030 01,242,241Mixed
BlackRock2,339,6200 00For
JANUS INVESTMENT FUND393,8850 0767,773Mixed
Bridge Builder Trust34,9180 0936,672Withhold
JPMorgan847,2770 00For
Charles Schwab836,9540 00For
DRIEHAUS MUTUAL FUNDS00 0759,548Withhold
Columbia Threadneedle741,7140 00For
American Century00 0722,721Withhold
Prudential/PGIM357,5330 098,165Mixed
Hartford367,6230 00For
TIAA356,5950 00For
IMPAX FUNDS SERIES TRUST I350,0000 00For
AMG FUNDS255,8120 00For
Jackson National00 0244,313Withhold
Equitable156,3560 075,390Mixed
Victory Capital7540 0226,114Withhold
Voya00 0201,990Withhold
TRUST FOR PROFESSIONAL MANAGERS00 0170,496Withhold
John Hancock73,5400 055,795Mixed
Dimensional00 0128,939Withhold
AIG/SunAmerica00 0120,117Withhold
Brinker Capital Destinations Trust2,3110 0103,846Withhold

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Elect Director: Weston Nichols, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 90,208,564WITHHELD: 6,777,840
Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Weston Nichols, Ph.D.

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Weston Nichols, Ph.D.”): 90,208,564 for, 6,777,840 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 47,506,873 for, 262,366 withheld, 17 abstained.

FOR
FOR: 47,506,873ABSTAIN: 17WITHHOLD: 262,366
Largest asset managers voting on “To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual mee” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,889,1360 00For
Vanguard13,888,3200 170For
T. Rowe Price4,979,7440 00For
BlackRock2,339,6200 00For
JANUS INVESTMENT FUND1,161,6580 00For
Bridge Builder Trust971,5900 00For
JPMorgan847,2770 00For
Charles Schwab836,9540 00For
DRIEHAUS MUTUAL FUNDS759,5480 00For
Columbia Threadneedle741,7140 00For
American Century722,7210 00For
Prudential/PGIM452,6000 03,098For
Hartford367,6230 00For
TIAA356,5950 00For
IMPAX FUNDS SERIES TRUST I350,0000 00For
AMG FUNDS255,8120 00For
Jackson National227,9770 016,336Mixed
Equitable156,3560 075,390Mixed
Victory Capital226,8680 00For
Voya201,9900 00For
TRUST FOR PROFESSIONAL MANAGERS170,4960 00For
John Hancock98,2690 031,066Mixed
Dimensional00 0128,939Withhold
AIG/SunAmerica120,1170 00For
Brinker Capital Destinations Trust106,1570 00For

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Approval, on an advisory basis, of the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 91,657,992AGAINST: 2,698,538

Prior year: 96.9% for (June 11, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 288 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 91,657,992 for, 2,698,538 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Crinetics Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 26 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 75 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,889,1360 00For
Vanguard13,878,8839,449 70For
T. Rowe Price4,979,7440 00For
BlackRock2,339,6200 00For
JANUS INVESTMENT FUND1,161,6580 00For
Bridge Builder Trust971,5900 00For
JPMorgan847,2770 00For
Charles Schwab836,9540 00For
DRIEHAUS MUTUAL FUNDS759,5480 00For
Columbia Threadneedle741,7140 00For
American Century0722,721 00Against
Prudential/PGIM455,6980 00For
Hartford367,6230 00For
TIAA356,5950 00For
IMPAX FUNDS SERIES TRUST I350,0000 00For
AMG FUNDS255,8120 00For
Jackson National244,3130 00For
Equitable231,7460 00For
Victory Capital226,8680 00For
Voya201,9900 00For
TRUST FOR PROFESSIONAL MANAGERS159,05611,440 00Mixed
John Hancock129,3350 00For
Dimensional128,9390 00For
AIG/SunAmerica120,1170 00For
Brinker Capital Destinations Trust106,1570 00For

Fund voting reports, all 75 managers: 46,991,174 for, 771,503 against, 5,978 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 236 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,434,4490 00For
T. Rowe Price7,266,0240 00For
Wellington6,405,1530 00For
Janus Henderson6,320,7940 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.5,647,1880 00For
DRIEHAUS CAPITAL MANAGEMENT LLC4,356,3450 00For
BlackRock2,867,4170 2750For
GEODE CAPITAL MANAGEMENT, LLC2,494,4480 00For
Polar Capital Holdings Plc2,198,2840 00For
PICTET ASSET MANAGEMENT SA1,859,7820 00For
Siren, L.L.C.1,753,6090 00For
BNP Paribas Asset Management Holding S.A.00 1,712,5240Abstain
First Light Asset Management, LLC1,477,0220 00For
RTW INVESTMENTS, LP1,447,8960 00For
GW&K Investment Management, LLC287,7950 00For
Novo Holdings A/S1,345,0710 00For
ORBIMED ADVISORS LLC999,0000 00For
ADAR1 Capital Management, LLC938,2530 00For
State Street930,144359 00For
Candriam S.C.A.00 892,3890Abstain
Vanguard863,4300 00For
Charles Schwab837,4550 00For
Aberdeen820,3950 00For
American Century0810,047 00Against
Northern Trust546,6540 00For

Institutional-manager reports, all 236 managers: 74,931,787 for, 1,893,079 against, 2,605,225 abstained, 1,643 not voted, 1,151,418 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%
FOR: 101,675,974AGAINST: 341,727

Prior year: 99.8% for (June 11, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 77 asset managers

Description as filed by funds: To ratify the selection of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

Crinetics Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Selection of Independent Registered Public Accounting Firm”): 101,675,974 for, 341,727 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 47,763,284 for, 1 against, 5,971 abstained.

FOR
FOR: 47,763,284AGAINST: 1ABSTAIN: 5,971
Largest asset managers voting on “To ratify the selection of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting ” at Crinetics Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,889,1360 00For
Vanguard13,888,3361 00For
T. Rowe Price4,979,7440 00For
BlackRock2,339,6200 00For
JANUS INVESTMENT FUND1,161,6580 00For
Bridge Builder Trust971,5900 00For
JPMorgan847,2770 00For
Charles Schwab836,9540 00For
DRIEHAUS MUTUAL FUNDS759,5480 00For
Columbia Threadneedle741,7140 00For
American Century722,7210 00For
Prudential/PGIM455,6980 00For
Hartford367,6230 00For
TIAA356,5950 00For
IMPAX FUNDS SERIES TRUST I350,0000 00For
AMG FUNDS255,8120 00For
Jackson National244,3130 00For
Equitable231,7460 00For
Victory Capital226,8680 00For
Voya201,9900 00For
TRUST FOR PROFESSIONAL MANAGERS170,4960 00For
John Hancock129,3350 00For
Dimensional128,9390 00For
AIG/SunAmerica120,1170 00For
Brinker Capital Destinations Trust106,1570 00For

Showing the 25 largest of 77 asset managers. All 77 are in the interactive database (link above).

Largest Crinetics Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 105,314,000 shares outstanding at the time of that meeting.

Fund voting reports: top Crinetics Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers as…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 15.09%
2Vanguard 13.19%
3T. Rowe Price 4.73%
4BlackRock 2.22%
5JANUS INVESTMENT FUND 1.10%
6Bridge Builder Trust 0.92%
7JPMorgan 0.80%
8Charles Schwab 0.79%
9DRIEHAUS MUTUAL FUNDS 0.72%
10Columbia Threadneedle 0.70%
Institutional-manager reports: top Crinetics Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers as…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.66%
2T. Rowe Price 6.90%
3Wellington 6.08%
4Janus Henderson 6.00%
5FARALLON CAPITAL MANAGEMENT, L.L.C. 5.36%
6DRIEHAUS CAPITAL MANAGEMENT LLC 4.14%
7BlackRock 2.72%
8GEODE CAPITAL MANAGEMENT, LLC 2.37%
9Polar Capital Holdings Plc 2.09%
10PICTET ASSET MANAGEMENT SA 1.77%

Reported Crinetics Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Crinetics Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)15,759,799 14.96%Form 13F, quarter ended March 31, 2026
FMR LLC13,957,269 13.25%Proxy statement (DEF 14A), table as of April 20, 2026
Vanguard Group9,135,504 8.67%Form 13F, quarter ended March 31, 2026
Farallon Capital Management, L.L.C.8,989,098 8.54%Schedule 13G, filed August 3, 2026
BlackRock8,478,815 8.05%Form 13F, quarter ended March 31, 2026
Wellington Management8,157,204 7.75%Form 13F, quarter ended March 31, 2026
Farallon Capital Partners, L.P.8,024,098 7.62%Proxy statement (DEF 14A), table as of April 20, 2026
DRIEHAUS CAPITAL MANAGEMENT LLC6,395,922 6.07%Schedule 13G, filed May 15, 2026
T. Rowe Price5,355,496 5.09%Form 13F, quarter ended March 31, 2026
R. Scott Struthers, Ph.D.2,578,188 2.45%Proxy statement (DEF 14A), table as of April 20, 2026

Percentages above are of 105,314,000 shares outstanding, as reported by Crinetics Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Crinetics Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 290 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,887 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — Crinetics Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Crinetics Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Crinetics Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Crinetics Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Crinetics Pharmaceuticals, Inc. 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crinetics-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.